Centene Corporation (CNC) $65.77
Centene is currently wrestling with a heavy supply zone near $66, leaving investors to wonder if the recent 17% rally has finally run out of steam.
52-wk High $69.36
📌 Investment Snapshot
- Current price of $65.77 sits 5.2% below the 52-week high of $69.36.
- Q2 2026 Revenue hit $53.58B with a solid EPS of $2.21, showing operational recovery.
- Technical Confluence Score of 90/100 reveals strong institutional support at lower levels.
- Analyst consensus remains a ‘Buy’ with a mean price target of $71.67.
⏳ WAIT
Centene shows impressive momentum but is currently overextended relative to its immediate support levels. The stock needs to digest recent gains before a sustainable move toward $70 can materialize.
| 📍 Entry Zone | $63.50 or below | 🛑 Stop-Loss | $60.40 |
| 📋 Adjust If | a daily close occurs above $68.00 with high volume | ||
The Investment Case — Why Now?
Over the last 90 days, Centene has transformed from a laggard into a sector leader, posting a 17.5% return that outpaces many managed care peers. This shift follows a decisive Q2 revenue beat of $53.58B, suggesting that the company’s restructuring efforts and Medicaid redetermination strategies are finally gaining traction. The market is now pricing in a return to stability after the significant EPS volatility seen in late 2025.
The primary risk remains the compressed margins within the government-sponsored segment, where rising medical loss ratios (MLR) could threaten the $2.21 EPS run rate. If the 10Y Treasury yield stays elevated at 4.66%, the valuation of high-revenue, low-margin insurers like Centene faces persistent headwind pressure. We are watching the $63.00 level closely to see if buyers defend the recent bullish Fair Value Gap.
Can Centene maintain its 17% quarterly momentum if the 10Y Treasury yield pushes toward 5%?
🤔 Can Centene maintain its 17% quarterly momentum if the 10Y Treasury yield pushes toward 5%?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Healthcare Plans |
| Headquarters | St. Louis, MO |
| Employees | 67,000+ |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Sell-side sweep at $67.64 on Aug 5
The price is currently sandwiched between the SMA50 ($64.29) and the upper Bollinger Band ($69.20), indicating a tightening range. While the SMA50 provides immediate support, the stock remains well above its SMA200 of $47.33, suggesting a potential mean reversion risk. A failure to hold the SMA50 would likely trigger a slide toward the $60 psychological level.
RSI at 49.8 confirms a total lack of directional conviction from the broader market participants this week. The MACD shows a razor-thin bullish crossover, but the ADX of 45.4 signals that the previous trend is exhausted. This divergence between price action and trend strength usually precedes a period of sideways consolidation.
Anchored VWAP from the 2025 lows sits way down at $41.09, highlighting how aggressive this year’s re-rating has been. The Volume Profile Point of Control (POC) at $38.42 remains the long-term gravitational center for this ticker. Current price action at $65.77 is testing the very top of the Value Area High ($66.34), a zone often met with heavy selling.
Recent liquidity sweeps at $67.64 and $64.95 suggest that institutional ‘smart money’ is actively hunting for orders in this $3 range. The unfilled bullish Fair Value Gap (FVG) between $62.55 and $63.48 acts as a magnet for price. We expect a dip into this zone to fill the gap before any serious attempt at new 52-week highs.
Historically, when CNC trades at this 52-week position (91.9%) with a neutral RSI, it enters a multi-week cooling-off period. The volume ratio of 0.66x confirms that the current upward nudge lacks the conviction of a true breakout. Staying on the sidelines until the $63.00 level is tested offers a much better risk-reward profile.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CNC | Centene Corporation | N/A |
| UNH | UnitedHealth Group | 22.4x |
| ELV | Elevance Health | 18.1x |
| CI | The Cigna Group | 15.5x |
| S&P 500 | Market Average | 21.2x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 2026 | $53.58B | $2.21 | +7.3% |
| Q1 2026 | $49.94B | $3.13 | +0.4% |
| Q4 2025 | $49.73B | $-2.24 | +0.1% |
| Q3 2025 | $49.69B | $-13.50 | -0.1% |
Centene generated a robust $3.4B in Free Cash Flow during the latest quarter, providing a significant liquidity cushion despite the lack of recent share buybacks.
The revenue trajectory is clearly accelerating, with Q2 2026 showing a significant jump to $53.58B. This suggests that the company is successfully navigating the post-pandemic Medicaid landscape. However, the massive losses in late 2025 still weigh on the trailing P/E, making traditional valuation metrics difficult to apply until more profitable quarters are stacked.
🚀 Growth Drivers — What Moves the Stock
- Medicaid Expansion 🟢 Upside Surprise — New state contracts and higher-than-expected retention rates are driving the $53B+ quarterly revenue run rate.
- Value-Based Care Pivot 🟡 Priced In — Shift toward lower-cost delivery models is beginning to stabilize the medical loss ratio (MLR).
- Marketplace Growth 🟢 Upside Surprise — Strong enrollment in the Health Insurance Marketplace segment is offsetting some Medicaid volatility.
🤔 Will the upcoming October earnings report confirm that the 2025 losses were a one-time anomaly or a structural flaw?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 39,822 |
| AQR Capital Management, LLC | 33,613 |
| Vanguard Capital Management LLC | 31,234 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| KENNETH A BURDICK | Director | 2026-06-10 | Purchase | 80,000 |
| PAUL J DIAZ | Director | 2026-07-28 | Purchase | 2,771 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 3.1% | 2.6 |
⚠ Key Risk Factors
~$1.2B impact
Valuation cap
~$500M impact
🎯 Guidance & Wall Street View
Management has signaled a focus on operational efficiency and margin expansion for the second half of 2026, targeting a more consistent EPS profile.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $85.00 | $71.67 | $56.00 | 18 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Neutral | $68.00 | 2026-08-04 | Maintained |
| Bernstein | Outperform | $75.00 | 2026-08-03 | Maintained |
| Barclays | Overweight | $78.00 | 2026-07-29 | Maintained |
Analysts are generally bullish on the recovery story, but recent ‘Neutral’ ratings from JP Morgan and Baird suggest the easy money has already been made in this leg of the rally.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Revenue acceleration to $53B+ proves market share dominance.
- Insider buying of 80,000 shares by Director Burdick signals deep value.
📊 Base Case
Centene consolidates between $60 and $68 as it works through the 2025 EPS overhang.
🐻 Bear Case
- Medical Loss Ratio (MLR) spikes due to unforeseen healthcare utilization.
- A break below SMA50 ($64.29) triggers a technical sell-off to $56.
🎯 Investor Action Plan — By Profile
The stock is currently overextended near the $66 resistance. Wait for a pullback to the $62.50-$63.50 bullish FVG zone to enter with a tighter stop at $60.40.
If you are already in, stay the course but do not add here. The 17.5% 3-month return is impressive, but the stock needs to prove it can hold the $64 level on volume.
The long-term recovery is promising, but the negative trailing EPS makes the current valuation opaque. Wait for the October earnings to confirm the margin expansion thesis.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is Centene's P/E ratio not available?
The P/E is currently unavailable because the company reported significant losses in late 2025, resulting in a negative trailing twelve-month EPS of $-10.36.
Q: What is the significance of the $63.2 buy-side sweep?
This level represents a zone where institutional buyers stepped in aggressively on July 23, marking it as a critical ‘floor’ for the current uptrend.
Q: Is the 4.66% Treasury yield a problem for CNC?
Yes, higher rates generally pressure the valuations of healthcare stocks and can increase the cost of debt for Centene’s ongoing operations.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Centene’s exposure to government contracts makes it sensitive to political and regulatory changes.
All active positions and their real-time performance are tracked on our Investment Log.
#CNC #Centene #HealthcareStocks #WallStreet #Investing #StockMarket #Medicaid #TechnicalAnalysis